All In Biotech

Free tool

FAERS Monitor: Gallium Citrate Ga 67

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018058 or its brand name (Gallium Citrate Ga 67, Gallium Citrate Ga-67). Reports on generic versions are filed under their own applications.

Reports

4

Serious

4

100% of reports

Hospitalization

4

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • erythema2
  • inflammation2
  • rash pruritic2
  • urticaria2
  • anaphylactic reaction1
  • blood pressure decreased1
  • cardiac arrest1
  • device related thrombosis1
  • electrocardiogram abnormal1
  • lung opacity1
  • off label use1
  • palpable purpura1
  • pulmonary oedema1
  • treatment noncompliance1
  • urine odour abnormal1

Reports by year received

View as table
YearReports
20211
20221
20231
20251

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,155 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
palpable purpura119280.43516.84,802
device related thrombosis15343.7977.61,334
lung opacity11996.0365.4498
urine odour abnormal1894.4163.8223
electrocardiogram abnormal1670.3122.7167
inflammation2203.876.5227
rash pruritic2194.172.8216
pulmonary oedema1117.521.528
treatment noncompliance196.117.623
anaphylactic reaction195.217.423
blood pressure decreased179.114.519
cardiac arrest163.711.715
urticaria262.823.668
erythema251.219.255
off label use16.01.11

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.